ATE407147T1 - Fab-fragmente humaner monoklonaler antikörper mit neutralisierender aktivität gegen das hcv e2 glycoprotein - Google Patents

Fab-fragmente humaner monoklonaler antikörper mit neutralisierender aktivität gegen das hcv e2 glycoprotein

Info

Publication number
ATE407147T1
ATE407147T1 AT03705004T AT03705004T ATE407147T1 AT E407147 T1 ATE407147 T1 AT E407147T1 AT 03705004 T AT03705004 T AT 03705004T AT 03705004 T AT03705004 T AT 03705004T AT E407147 T1 ATE407147 T1 AT E407147T1
Authority
AT
Austria
Prior art keywords
glycoprotein
neutralizing activity
monoclonal antibodies
activity against
human monoclonal
Prior art date
Application number
AT03705004T
Other languages
English (en)
Inventor
Roberto Burioni
Original Assignee
Roberto Burioni
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roberto Burioni filed Critical Roberto Burioni
Application granted granted Critical
Publication of ATE407147T1 publication Critical patent/ATE407147T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/118—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT03705004T 2002-01-30 2003-01-29 Fab-fragmente humaner monoklonaler antikörper mit neutralisierender aktivität gegen das hcv e2 glycoprotein ATE407147T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2002RM000049A ITRM20020049A1 (it) 2002-01-30 2002-01-30 Frammenti fab di anticorpi monoclonali umani diretti contro la glicoproteina e2 di hcv e dotati di potere neutralizzante in vitro.

Publications (1)

Publication Number Publication Date
ATE407147T1 true ATE407147T1 (de) 2008-09-15

Family

ID=11456013

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03705004T ATE407147T1 (de) 2002-01-30 2003-01-29 Fab-fragmente humaner monoklonaler antikörper mit neutralisierender aktivität gegen das hcv e2 glycoprotein

Country Status (17)

Country Link
US (2) US20050084845A1 (de)
EP (1) EP1476468B9 (de)
JP (1) JP4287280B2 (de)
KR (1) KR101002791B1 (de)
CN (1) CN1856508A (de)
AT (1) ATE407147T1 (de)
AU (1) AU2003208000B2 (de)
CA (1) CA2474801C (de)
DE (1) DE60323333D1 (de)
DK (1) DK1476468T3 (de)
EA (1) EA009861B1 (de)
ES (1) ES2314179T3 (de)
IT (1) ITRM20020049A1 (de)
NZ (1) NZ534922A (de)
RU (1) RU2004126238A (de)
WO (1) WO2003064473A2 (de)
ZA (1) ZA200406187B (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7727962B2 (en) 2004-05-10 2010-06-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder comprising new compositions of oligosaccharides and methods for their preparation
US7723306B2 (en) 2004-05-10 2010-05-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation
US7611709B2 (en) * 2004-05-10 2009-11-03 Boehringer Ingelheim Pharma Gmbh And Co. Kg 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
ITTO20070066A1 (it) 2007-01-30 2008-07-31 Pomona Biotechnologies Llc Anticorpi monoclonali anti-idiotipo mimotopi dell'antigene gp 120 di hiv
EP2134748A1 (de) * 2007-03-06 2009-12-23 Ribovax Biotechnologies SA Gegen das rubella-virus spezifische antikörper
JPWO2009014216A1 (ja) 2007-07-25 2010-10-07 国立感染症研究所長 Ｃ型肝炎ウイルス（ｈｃｖ）に対して感染阻害活性を有する抗体およびその用途
JP5763344B2 (ja) * 2007-12-17 2015-08-12 メディカル リサーチ カウンシル テクノロジー Ｃ型肝炎ウイルス抗体
ITTO20080204A1 (it) 2008-03-17 2009-09-18 Pomona Biotechnologies Llc Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
ITTO20080398A1 (it) 2008-05-27 2009-11-28 Pomona Biotechnologies Llc Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1
WO2010035292A1 (en) * 2008-09-24 2010-04-01 Natimab Therapeutics S.R.L. The use of a human monoclonal anti-hcv antibody as a medicament for the therapeutic treatment and prevention of hcv infections
US20100104555A1 (en) * 2008-10-24 2010-04-29 The Scripps Research Institute HCV neutralizing epitopes
ITTO20080964A1 (it) 2008-12-22 2010-06-23 Natimab Therapeutics S R L Anticorpo monoclonale anti-hcv come medicamento per il trattamento terapeutico e la prevenzione di infezioni da hcv
IT1395961B1 (it) 2009-06-01 2012-11-02 Pomona Biotechnologies Llc Anticorpi monoclonali come medicamento per il trattamento terapeutico e/o profilattico delle infezioni da virus influenzale a (h1n1) di origine suina (s-oiv)
US8592559B2 (en) 2009-10-30 2013-11-26 Toray Industries, Inc. Antibody having activity of inhibiting hepatitis C virus (HCV) infection and use thereof
US9719141B2 (en) 2010-03-01 2017-08-01 Vincent Agnello Prognostic marker for cryoglobulinemic vasculitis and B cell malignancies in HCV infected patients
CN104119436B (zh) * 2013-04-27 2016-12-28 中国科学院上海生命科学研究院 抗丙型肝炎病毒的中和性全人单克隆抗体
GB201415714D0 (en) * 2014-09-05 2014-10-22 Medical Res Council Antibodies and antigen binding fragments thereof
CN105254756B (zh) * 2015-11-27 2018-09-07 武汉大学 一种针对丙型肝炎病毒包膜蛋白e2的单克隆抗体及应用
KR20180001380U (ko) 2016-10-31 2018-05-10 대우조선해양 주식회사 해양구조물의 발로 작동시키는 캡스탄
CN118459597A (zh) 2019-12-27 2024-08-09 凯奥目生物科学株式会社 抗cdcp1抗体
CN116963779A (zh) 2020-09-02 2023-10-27 国立大学法人东京大学 癌症免疫微环境的调节物质及其预防、诊断或治疗
JPWO2024024565A1 (de) 2022-07-28 2024-02-01

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1325517C (zh) * 1998-07-21 2007-07-11 展马博联合股份有限公司 抗丙型肝炎病毒抗体及其用途
US7091324B2 (en) * 1998-11-05 2006-08-15 Board Of Trustees Of Leland Stanford Junior University Prevention and treatment of HCV infection employing antibodies directed against conformational epitopes
AU2001273363A1 (en) 2000-07-12 2002-01-21 General Instrument Corporation Method and apparatus for downloading objects via an inband channel with minimal subscriber impact
CA2429946A1 (en) * 2000-12-01 2002-07-18 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Monoclonal antibodies specific for the e2 glycoprotein of hepatitis c virus and their use in the diagnosis, treatment, and prevention of hepatitis c

Also Published As

Publication number Publication date
RU2004126238A (ru) 2005-04-20
DK1476468T3 (da) 2009-01-19
CA2474801A1 (en) 2003-08-07
EP1476468B1 (de) 2008-09-03
EA200401081A1 (ru) 2005-10-27
ITRM20020049A0 (it) 2002-01-30
JP4287280B2 (ja) 2009-07-01
AU2003208000B2 (en) 2010-05-20
KR101002791B1 (ko) 2010-12-21
US7727529B2 (en) 2010-06-01
US20080241162A1 (en) 2008-10-02
ITRM20020049A1 (it) 2003-07-30
CN1856508A (zh) 2006-11-01
CA2474801C (en) 2012-03-20
US20050084845A1 (en) 2005-04-21
EP1476468B9 (de) 2009-04-08
KR20040077745A (ko) 2004-09-06
JP2005531286A (ja) 2005-10-20
ZA200406187B (en) 2006-06-28
EP1476468A2 (de) 2004-11-17
WO2003064473A2 (en) 2003-08-07
EA009861B1 (ru) 2008-04-28
NZ534922A (en) 2008-07-31
WO2003064473A3 (en) 2003-12-24
DE60323333D1 (de) 2008-10-16
ES2314179T3 (es) 2009-03-16

Similar Documents

Publication Publication Date Title
ATE407147T1 (de) Fab-fragmente humaner monoklonaler antikörper mit neutralisierender aktivität gegen das hcv e2 glycoprotein
EA201300022A1 (ru) Терапевтическое человеческое моноклональное антитело против il-1r1
EP1383785A4 (de) Rekombinanter, tumorspezifischer antikörper und dessen verwendung
DK1534335T3 (da) FcgammaRIIB-specifikke antistoffer og fremgangsmåder til anvendelse deraf
DE60220719D1 (de) Antikörper gegen das muc18-antigen
UA109633C2 (uk) Антитіло людини проти тканинного фактора
ATE471946T1 (de) Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2
CR8108A (es) Tratamiento con anticuerpos anti-vegf
EA200300628A1 (ru) Соединения, специфические к аденозиновому a, aи aрецептору, и их применение
DK1140170T3 (da) Antistoffragmenter til topisk behandling af öjensygdomme
EP1467757A4 (de) Verwendung von antikörpern gegen das muc18-antigen
NZ527283A (en) Modified antibodies and methods of use
EA201100694A1 (ru) Антитело к cd38 человека и его применение
WO2001068708A3 (en) Human and humanized fap-alpha-specific antibodies
WO2005120557A3 (en) Inhibition of macrophage-stimulating protein receptor (ron)
DE60141297D1 (de) Gegen das menschliche bst2 antigen gerichteter monoklonaler antikörper
WO2001037874A3 (en) Treatment of psoriasis by using an antibody to tnf alpha
WO2006137938A3 (en) Antibody fragments for protection from pathogen infection and methods of use thereof
WO2004018519A3 (en) Therapeutic uses of monoclonal antibodies to the angiotensin-ii type-1 receptor
WO2003097082A3 (en) Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies
EP1748075A4 (de) Rekombinanter chemokin-antigenimpfstoff
WO2001072334A3 (en) Methods for treating disease with antibodies to cxcr3
WO2006113723A3 (en) Compositions and methods for diagnosing, predicting therapeutic response of, and monitoring autoimmune disease
WO2023159061A3 (en) Human monoclonal antibodies targeting the s2 subunit of the sars-cov-2 spike protein
WO2004035003A3 (en) Therapeutic adjuvant

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties